Benzinga | Jan 28, 2021 08:36AM EST

Predictive Oncology Subsidiary Soluble Biotech Announces Contract With Pharmaceutical Company To 'improve the solubility and stability of a protein therapeutic destined for future clinical use'

MINNEAPOLIS, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a knowledge-driven company focused on applying artificial intelligence ("AI") to personalized medicine and drug discovery, announced today that its wholly owned subsidiary Soluble Biotech, Inc. just inked another contract with a large pharmaceutical company. The work will involve using Soluble Biotech's proprietary protein formulation technology to improve the solubility and stability of a protein therapeutic destined for future clinical use.



"This opportunity may also lead to a long-term relationship whereby Soluble Biotech develops a strategic partnership to support several other therapeutics currently under development within the pharmaceutical company," said Dr. Larry DeLucas, Founder and President of Soluble Biotech, Inc.